Mersana Therapeutics
MRSN
MRSN was delisted on the 5th of January, 2026.
152 hedge funds and large institutions have $593M invested in Mersana Therapeutics in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 69 increasing their positions, 35 reducing their positions, and 19 closing their positions.
97% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 35
9% more call options, than puts
Call options by funds: $512K | Put options by funds: $469K
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
0.26% more ownership
Funds ownership: 3.8% → 4.06% (+0.26%)
0% more funds holding
Funds holding: 152 → 152 (0)
5% less capital invested
Capital invested by funds: $623M → $593M (-$30.6M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$13.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$12.1M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$6.42M |
| 4 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
+$3.83M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$3.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$3.57M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.98M |
| 3 |
Goldman Sachs
New York
|
-$2.63M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.95M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$984K |
MRSN Hedge Fund Activity: Q4 2022 in Review
152 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Mersana Therapeutics (MRSN) for Q4 2022, worth a combined $593M — down 4.9% from $623M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MRSN positions and 19 closed out — a net gain of 1 holder — while 69 added to existing stakes and 35 trimmed.
The largest buyer was Marshall Wace, adding an estimated $13.5M. The largest seller was Invesco, cutting an estimated $3.57M.
- 152 institutional investors held Mersana Therapeutics (MRSN) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $593M of Mersana Therapeutics stock for Q4 2022, down 4.9% quarter-over-quarter.
- 20 funds opened new Mersana Therapeutics positions in Q4 2022 and 19 closed out, a net change of +1 holder.
- The largest Mersana Therapeutics buyer in Q4 2022 was Marshall Wace, an estimated $13.5M added.
- The largest Mersana Therapeutics seller in Q4 2022 was Invesco, an estimated $3.57M sold.
Based on aggregated 13F filings for Q4 2022.